Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer

0
0 / 5 (0 votos)

Oncology: International Journal of Cancer Research and Treatment

Published online: November 2017

DOI: https://doi.org/10.1159/000479154

Berenato R.a · Morano F.a · Pietrantonio F.a · Cotsoglou C.b · Caporale M.a · Infante G.c ·Pellegrinelli A.d · Alessi A.e · Battiston C.b · Coppa J.b · Padovano B.e · Mennitto A.a · Niger M.a ·Fucà G.a · Lazzati S.a · Greco G.f · Delconte G.g · de Braud F.a, h · Mazzaferro V.b, h · Di Bartolomeo M.a 

Background:  This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

Seguir leyendo